https://www.pharmaradar360.com/article/bio-2026-us-needs-to-dodge-china-s-inescapable-dependencies-to-protect-biotech-641507cd70ca8b4fPharma Surgeen2026-06-24T11:23:31.000ZBIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotechhttps://www.pharmaradar360.com/article/helus-pharma-provides-update-on-approach-phase-3-trial-enrollment-progress-8a40d76634fb17b2Pharma Surgeen2026-06-24T11:23:05.000ZHelus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progresshttps://www.pharmaradar360.com/article/drug-compounding-was-meant-for-individuals-empower-pharmacy-serves-70k-a-week-c7cc65d12a4e7763Pharma Surgeen2026-06-24T11:10:59.000ZDrug compounding was meant for individuals. Empower Pharmacy serves 70K a week.https://www.pharmaradar360.com/article/ockenden-review-into-maternity-services-at-nottingham-university-hospitals-nhs-t-36fe922f80f82f6dPharma Surgeen2026-06-24T11:06:27.000ZOckenden review into maternity services at Nottingham University Hospitals NHS Trust: final reporthttps://www.pharmaradar360.com/article/ophthalmology-venture-grabs-investors-attention-raises-330-million-da66c414c437d06cPharma Surgeen2026-06-24T11:04:40.000ZOphthalmology venture grabs investors’ attention, raises $330 millionhttps://www.pharmaradar360.com/article/veraxa-adds-60-more-lab-space-in-heidelberg-for-cancer-drug-work-a5cd98c6364b3f8dPharma Surgeen2026-06-24T11:00:00.000ZVERAXA adds 60% more lab space in Heidelberg for cancer drug workhttps://www.pharmaradar360.com/article/fda-gives-calcimedica-no-comments-on-auxora-safety-review-b825359f44b822efPharma Surgeen2026-06-24T11:00:00.000ZFDA gives CalciMedica no comments on Auxora safety reviewhttps://www.pharmaradar360.com/article/ollin-hauls-in-330m-to-enlist-vabysmo-challenger-in-phase-3-eye-disease-gauntlet-d915e0de9d7fa235Pharma Surgeen2026-06-24T11:00:00.000ZOllin hauls in $330M to enlist Vabysmo challenger in phase 3 eye disease gauntlethttps://www.pharmaradar360.com/article/what-does-practical-sustainability-in-api-manufacturing-really-look-like-03e54795f2fc6509Pharma Surgeen2026-06-24T10:59:30.000ZWhat does practical sustainability in API manufacturing really look like?https://www.pharmaradar360.com/article/oura-and-lilly-join-forces-to-harmonise-drug-wearable-obesity-care-a8b25e8ea8fe1a57Pharma Surgeen2026-06-24T10:47:40.000ZŌURA and Lilly join forces to harmonise drug-wearable obesity carehttps://www.pharmaradar360.com/article/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedot-e83dd7d232ad217aPharma Surgeen2026-06-24T10:45:00.000ZEuropean Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/how-ups-is-adressing-pharmaceutical-procurement-challenges-1b0816db0394ea17Pharma Surgeen2026-06-24T10:08:07.000ZHow UPS is Adressing pharmaceutical Procurement Challengeshttps://www.pharmaradar360.com/article/helus-pharma-says-phase-3-depression-trial-is-86-enrolled-7486167422b33d49Pharma Surgeen2026-06-24T10:00:00.000ZHelus Pharma says Phase 3 depression trial is 86% enrolledhttps://www.pharmaradar360.com/article/corxel-s-oral-obesity-drug-clears-phase-ii-test-e7b35f5ebfeb9d53Pharma Surgeen2026-06-24T09:20:46.000ZCORXEL’s oral obesity drug clears Phase II testhttps://www.pharmaradar360.com/article/sangamo-files-for-bankruptcy-as-lilly-and-astellas-target-assets-22193f6d97baac4cPharma Surgeen2026-06-24T09:08:55.000ZSangamo files for bankruptcy as Lilly and Astellas target assetshttps://www.pharmaradar360.com/article/former-vertex-gsk-exec-launches-science-first-pet-nutrition-company-53f3d6ffcacd61d5Pharma Surgeen2026-06-24T09:08:00.000ZFormer Vertex, GSK exec launches science-first pet nutrition companyhttps://www.pharmaradar360.com/article/early-biomarkers-as-predictors-of-nephrology-trial-trajectory-d234490e2abe5e9ePharma Surgeen2026-06-24T08:53:01.000ZEarly Biomarkers as Predictors of Nephrology Trial Trajectoryhttps://www.pharmaradar360.com/article/the-things-to-think-about-before-taking-your-biotech-company-public-3472dda2cc6cc70fPharma Surgeen2026-06-24T07:50:03.000ZThe Things to Think About Before Taking Your Biotech Company Publichttps://www.pharmaradar360.com/article/pharmaceutical-omega-3-api-market-to-reach-usd-2-3-billion-by-2036-as-prescripti-83447f70072dadafPharma Surgeen2026-06-24T07:02:01.000ZPharmaceutical Omega-3 API Market to Reach USD 2.3 Billion by 2036 as Prescription Cardiovascular Therapies Drive Demand for High-Purity EPA APIs, FMIhttps://www.pharmaradar360.com/article/coiled-therapeutics-appoints-biotech-veteran-craig-tooman-to-board-1fc0eabf27f963a5Pharma Surgeen2026-06-24T06:56:00.000ZCoiled Therapeutics appoints biotech veteran Craig Tooman to boardhttps://www.pharmaradar360.com/article/when-your-sponsor-gets-acquired-mid-trial-your-site-pays-the-operational-price-5d99f0b797d5c58fPharma Surgeen2026-06-24T06:52:59.000ZWhen Your Sponsor Gets Acquired Mid-Trial, Your Site Pays the Operational Pricehttps://www.pharmaradar360.com/article/first-aid-socialists-target-biotech-sweetener-64428c78af11f7e3Pharma Surgeen2026-06-24T06:52:03.000ZFIRST AID: Socialists target biotech sweetenerhttps://www.pharmaradar360.com/article/mckesson-selects-moore-oklahoma-for-179-million-state-of-the-art-pharmaceutical-fd5cf5e31cb48e12Pharma Surgeen2026-06-24T06:35:00.000ZMcKesson Selects Moore, Oklahoma for $179 Million State-of-the-Art Pharmaceutical Distribution Centerhttps://www.pharmaradar360.com/article/bio-usa-korean-biotech-has-innovation-now-it-needs-capital-13c2f930339dcaeaPharma Surgeen2026-06-24T06:30:11.000Z[Bio USA] Korean biotech has innovation. Now it needs capitalhttps://www.pharmaradar360.com/article/unixell-biotechnology-secures-fda-ind-clearance-for-ux-da003-achieving-china-u-s-6074a2411a1b8ca8Pharma Surgeen2026-06-24T06:25:22.000ZUniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson's Therapyhttps://www.pharmaradar360.com/article/pharma-ai-summer-update-preview-drive-the-future-of-pharmaceutical-intelligence-216a46d92fa7b3cfPharma Surgeen2026-06-24T05:23:42.000ZPharma.AI Summer Update Preview: Drive the future of pharmaceutical intelligencehttps://www.pharmaradar360.com/article/araris-biotech-ag-and-taiho-oncology-announce-dosing-of-first-patient-in-phase-1-524924865415451bPharma Surgeen2026-06-24T05:06:30.000ZAraris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphomahttps://www.pharmaradar360.com/article/reuters-health-news-summary-830b6b2e738c63e2Pharma Surgeen2026-06-24T04:59:21.000ZReuters Health News Summaryhttps://www.pharmaradar360.com/article/is-west-pharmaceutical-services-wst-pricey-as-glp-1-demand-lifts-expectations-c298653e5750d138Pharma Surgeen2026-06-24T04:57:22.000ZIs West Pharmaceutical Services (WST) Pricey As GLP 1 Demand Lifts Expectations?https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-stock-after-94-one-year-surge-is-the-price-j-3a182297afe4369ePharma Surgeen2026-06-24T03:28:00.000ZTeva Pharmaceutical Industries (TEVA) Stock After 94% One-Year Surge Is The Price Justifiedhttps://www.pharmaradar360.com/article/recce-pharmaceuticals-seeks-10m-capital-injection-0d20182ec834882bPharma Surgeen2026-06-24T03:28:00.000ZRecce Pharmaceuticals seeks $10m capital injectionhttps://www.pharmaradar360.com/article/pharmac-introduces-a-new-vision-and-strategic-priorities-640e013d777e6b11Pharma Surgeen2026-06-24T02:00:00.000ZPharmac introduces a new vision and strategic prioritieshttps://www.pharmaradar360.com/article/pharmac-funds-another-adhd-medicine-to-improve-supply-1ff120e85d863311Pharma Surgeen2026-06-24T02:00:00.000ZPharmac funds another ADHD medicine to improve supplyhttps://www.pharmaradar360.com/article/new-agreement-to-save-hospitals-millions-2c2ea1d39fa2ac7ePharma Surgeen2026-06-24T02:00:00.000ZNew agreement to save hospitals millionshttps://www.pharmaradar360.com/article/otsuka-america-establishes-the-pocari-sweat-science-advisory-boardannounces-new-cdb07cd89e3d2a03Pharma Surgeen2026-06-24T01:00:00.000ZOtsuka America Establishes the POCARI SWEAT SCIENCE ADVISORY BOARDAnnounces New Heat Illness Prevention Guidance to Address Heat Challenges in the United Stateshttps://www.pharmaradar360.com/article/global-pharma-leadership-voices-the-future-of-pharmaceutical-innovation-begins-w-60ee3994fa4ec79fPharma Surgeen2026-06-24T00:40:00.000Z[Global Pharma Leadership Voices] The future of pharmaceutical innovation begins where patients still waithttps://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-40300354bf791c91Pharma Surgeen2026-06-24T00:00:00.000ZNovo Nordisk filed Form 6-Khttps://www.pharmaradar360.com/article/new-treatment-option-recommended-for-recurrent-or-metastatic-cervical-cancer-eba35bc6e2bc0451Pharma Surgeen2026-06-24T00:00:00.000ZNew treatment option recommended for recurrent or metastatic cervical cancerhttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-06-24T00:00:00.000ZView all news articleshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-90909cbf8abd046cPharma Surgeen2026-06-24T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-df0ec1fcc994385aPharma Surgeen2026-06-24T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-5c20e9aa3deaaa9dPharma Surgeen2026-06-24T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-5964c33eb4a2d83cPharma Surgeen2026-06-24T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-66103c9c2c23ce4bPharma Surgeen2026-06-24T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-fdc071a5910fc62ePharma Surgeen2026-06-24T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-b63a525872566d9dPharma Surgeen2026-06-24T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-50e088fb55c1d92bPharma Surgeen2026-06-24T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-39b49d88c0713289Pharma Surgeen2026-06-24T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-d3d3923d09684c3cPharma Surgeen2026-06-24T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-58ba068f161a4c9fPharma Surgeen2026-06-24T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-da37ac21ff995968Pharma Surgeen2026-06-24T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-48c9a6ebde6323aePharma Surgeen2026-06-24T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-912f21e7f2affe4ePharma Surgeen2026-06-24T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-893712ea7fe33d49Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Chickens-Gallus Gallus; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-9bef3f045ec8bb7bPharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Felines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-4b2127e4ff8aa50ePharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Canines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-583c826a02c7beafPharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Porcines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-cae154bf8e2386e6Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Equines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-600224bd5b51ad56Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Caprines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-54092ff28d3b41e9Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Ovines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-25780f641f4d8a04Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Bovines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-31a2c3e7954c060ePharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: General Recommendations; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/medicare-and-state-health-care-programs-fraud-and-abuse-request-for-information-947a786c40a2498cPharma Surgeen2026-06-24T00:00:00.000ZMedicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Federal Anti-Kickback Statute and Beneficiary Inducements CMPhttps://www.pharmaradar360.com/article/schedules-of-controlled-substances-temporary-placement-of-o-desmethyltramadol-in-4520029496532faePharma Surgeen2026-06-24T00:00:00.000ZSchedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule Ihttps://www.pharmaradar360.com/article/schedules-of-controlled-substances-placement-of-bromazolam-in-schedule-i-correct-e44a3995822493b1Pharma Surgeen2026-06-24T00:00:00.000ZSchedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correctionhttps://www.pharmaradar360.com/article/amanda-ward-n-d-decision-and-order-e801daf927427c9aPharma Surgeen2026-06-24T00:00:00.000ZAmanda Ward, N.D.; Decision and Orderhttps://www.pharmaradar360.com/article/irina-gross-d-p-m-decision-and-order-74c76b404fcf3298Pharma Surgeen2026-06-24T00:00:00.000ZIrina Gross, D.P.M.; Decision and Orderhttps://www.pharmaradar360.com/article/fiscal-year-fy-2026-notice-of-supplemental-funding-opportunity-963d21b3c27713dePharma Surgeen2026-06-24T00:00:00.000ZFiscal Year (FY) 2026 Notice of Supplemental Funding Opportunityhttps://www.pharmaradar360.com/article/demonstrating-substantial-evidence-of-effectiveness-for-human-drug-and-biologica-08058812b8eab8c7Pharma Surgeen2026-06-24T00:00:00.000ZDemonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products; Revised Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/expedited-investigational-new-drug-pilot-program-request-for-information-d835e05efeee33d7Pharma Surgeen2026-06-24T00:00:00.000ZExpedited Investigational New Drug Pilot Program; Request for Informationhttps://www.pharmaradar360.com/article/master-protocols-for-drug-and-biological-product-development-draft-guidance-for-1fe1f9759aa3f262Pharma Surgeen2026-06-24T00:00:00.000ZMaster Protocols for Drug and Biological Product Development; Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/quantitative-systems-pharmacology-qsp-based-dose-selection-for-minimum-anticipat-b46e928ff4245d85Pharma Surgeen2026-06-24T00:00:00.000ZQuantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials; Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/office-of-the-director-national-institutes-of-health-notice-of-closed-meeting-1a544af7d7fe2ed5Pharma Surgeen2026-06-24T00:00:00.000ZOffice of the Director, National Institutes of Health; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/anesthesia-strategy-and-clinical-outcomes-in-ruptured-aortic-aneurysm-repair-ins-1d6639903b916616Pharma Surgeen2026-06-24T00:00:00.000ZAnesthesia Strategy and Clinical Outcomes in Ruptured Aortic Aneurysm Repair: Insights from EVAR and TEVARhttps://www.pharmaradar360.com/article/multi-target-mechanism-of-action-of-curcumin-in-rheumatoid-arthritis-and-clinica-60acd8593ec02f49Pharma Surgeen2026-06-24T00:00:00.000ZMulti-target Mechanism of Action of Curcumin in Rheumatoid Arthritis and Clinical Applicationhttps://www.pharmaradar360.com/article/role-of-tumor-markers-and-cytokines-in-the-pathogenesis-of-lung-cancer-ce787bcfbc03f090Pharma Surgeen2026-06-24T00:00:00.000ZRole of tumor markers and cytokines in the pathogenesis of lung cancerhttps://www.pharmaradar360.com/article/prominent-crosstalks-between-perineural-invasion-and-immunosuppressive-tumor-mic-afe5af6ada1b347fPharma Surgeen2026-06-24T00:00:00.000ZProminent crosstalks between perineural invasion and immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinomahttps://www.pharmaradar360.com/article/radiation-induced-cardiotoxicity-in-lung-cancer-current-landscape-and-future-dir-d87c06d8e2adf7d6Pharma Surgeen2026-06-24T00:00:00.000ZRadiation-induced cardiotoxicity in lung cancer: Current landscape and future directionshttps://www.pharmaradar360.com/article/letter-to-the-editor-yin-yang-1-in-inflammatory-memory-and-progression-susceptib-5055a860a59d8d08Pharma Surgeen2026-06-24T00:00:00.000ZLetter to the Editor: Yin Yang 1 in inflammatory memory and progression susceptibility in <i>Helicobacter pylori</i> –associated gastric cancerhttps://www.pharmaradar360.com/article/myo-inositol-and-d-chiro-inositol-in-polycystic-ovary-syndrome-mechanisms-of-act-da773c4ee911c586Pharma Surgeen2026-06-24T00:00:00.000ZMYO-INOSITOL AND D-CHIRO-INOSITOL IN POLYCYSTIC OVARY SYNDROME: MECHANISMS OF ACTION, CLINICAL EFFECTIVENESS, SAFETY, AND CURRENT LIMITATIONS: A NARRATIVE REVIEWhttps://www.pharmaradar360.com/article/effect-of-minimizing-light-exposure-with-digital-visualization-on-macular-functi-f8f9bc8f3ccfad66Pharma Surgeen2026-06-24T00:00:00.000ZEffect of Minimizing Light Exposure with Digital Visualization on Macular Function After Cataract Surgery in Patients with AMD: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/clinical-evaluation-of-a-combined-deep-learning-reconstructed-readout-segmented-467bf16bdca5a1b8Pharma Surgeen2026-06-24T00:00:00.000ZClinical Evaluation of a Combined Deep Learning–Reconstructed Readout-Segmented Echo-Planar Imaging and Water-Excitation Spectral Fat-Saturation Protocol for Breast Diffusion-Weighted Imaging at 3T Breast MRIhttps://www.pharmaradar360.com/article/promoting-physical-activity-and-reducing-sedentary-behavior-in-adults-with-type-e84257bf2f8ecbb7Pharma Surgeen2026-06-24T00:00:00.000ZPromoting Physical Activity and Reducing Sedentary Behavior in Adults with Type 2 Diabetes: Study Protocol of the DIA/01 Randomized Trialhttps://www.pharmaradar360.com/article/drug-repurposing-of-sophoridine-for-sepsis-induced-organ-injury-from-in-depth-an-4bcd17ca73223be2Pharma Surgeen2026-06-24T00:00:00.000ZDrug repurposing of sophoridine for sepsis-induced organ injury: from in-depth analysis of a single agent to a multi-target therapeutic paradigmhttps://www.pharmaradar360.com/article/methodologies-for-generating-and-evaluating-clinical-and-performance-evidence-fo-ef640109401d5054Pharma Surgeen2026-06-24T00:00:00.000ZMethodologies for generating and evaluating clinical and performance evidence for high-risk and innovative medical devices and in vitro diagnostics: a scoping reviewhttps://www.pharmaradar360.com/article/bridging-the-theory-practice-gap-in-laboratory-medicine-development-and-applicat-b0c7f3f0f1e62cd1Pharma Surgeen2026-06-24T00:00:00.000ZBridging the theory-practice gap in laboratory medicine: development and application of a standardized case library for fostering clinical reasoning in postgraduate traininghttps://www.pharmaradar360.com/article/fd571a746e1226d9Pharma Surgeen2026-06-24T00:00:00.000ZГіперімуноглобулінемія Е як причина тяжкого хронічного інфекційного ураження шкіри: клінічний випадокhttps://www.pharmaradar360.com/article/bea11ce3a6d7af0aPharma Surgeen2026-06-24T00:00:00.000ZДезлоратадин у сучасній системі пероральної доставки ліків: вартий вибір для належного лікування алергічних захворюваньhttps://www.pharmaradar360.com/article/high-concordance-in-molecular-profiles-between-primary-tumors-and-matched-lymph-d9efdb0ab1933651Pharma Surgeen2026-06-24T00:00:00.000ZHigh Concordance in Molecular Profiles Between Primary Tumors and Matched Lymph Node Metastases in Differentiated Thyroid Carcinoma: Implications for Clinical Sample Selectionhttps://www.pharmaradar360.com/article/immune-related-liver-injury-clinical-and-histological-subtyping-defines-distinct-643442e1a8d0cf98Pharma Surgeen2026-06-24T00:00:00.000ZImmune-related liver injury: Clinical and histological subtyping defines distinct trajectories and therapeutic implicationshttps://www.pharmaradar360.com/article/clinical-outcomes-of-6-fr-vs-8-fr-catheters-in-percutaneous-transhepatic-gallbla-aee4660af5453f30Pharma Surgeen2026-06-24T00:00:00.000ZClinical Outcomes of 6-Fr vs 8-Fr Catheters in Percutaneous Transhepatic Gallbladder Drainage: A Propensity Score-Matched Analysishttps://www.pharmaradar360.com/article/genomic-characterization-of-the-first-near-complete-goat-associated-orf-virus-ge-14d0cfee7040ef92Pharma Surgeen2026-06-24T00:00:00.000ZGenomic characterization of the first near-complete goat-associated Orf virus genome sequenced directly from a human clinical sample in Portugalhttps://www.pharmaradar360.com/article/predictors-of-achieving-remission-in-rheumatoid-arthritis-during-levilimab-thera-fa99a26b1e400d79Pharma Surgeen2026-06-24T00:00:00.000ZPredictors of achieving remission in rheumatoid arthritis during levilimab therapy in real-world clinical practicehttps://www.pharmaradar360.com/article/lupus-nephritis-in-patients-from-kyrgyzstan-clinical-and-laboratory-manifestatio-23e8bc4d1c06f8b1Pharma Surgeen2026-06-24T00:00:00.000ZLupus nephritis in patients from Kyrgyzstan: clinical and laboratory manifestations, disease course variants, and prognostic factors for developmenthttps://www.pharmaradar360.com/article/prospective-evaluation-of-the-effect-of-stopping-estrogen-containing-contracepti-f16ae0b12c1bc94ePharma Surgeen2026-06-24T00:00:00.000ZProspective evaluation of the effect of stopping estrogen-containing contraceptives on serum CBG and cortisol levelshttps://www.pharmaradar360.com/article/does-metabolically-healthy-obesity-really-exist-going-toward-new-definitions-d96a5263e512ff66Pharma Surgeen2026-06-24T00:00:00.000ZDoes Metabolically Healthy Obesity Really Exist: Going Toward New Definitionshttps://www.pharmaradar360.com/article/deciphering-the-role-of-adipose-tissue-microbial-dna-in-obesity-related-metaboli-256959ccde3d7740Pharma Surgeen2026-06-24T00:00:00.000ZDeciphering the role of adipose tissue microbial DNA in obesity-related metabolic dysfunctionhttps://www.pharmaradar360.com/article/how-glycemic-variability-trajectories-impact-clinical-outcomes-in-critically-ill-bf8cff916ec6365bPharma Surgeen2026-06-24T00:00:00.000ZHow glycemic variability trajectories impact clinical outcomes in critically ill patients with severe pneumonia: a prospective cohort studyhttps://www.pharmaradar360.com/article/a-pragmatic-smart-study-of-medication-and-cbt-sequencing-in-pediatric-anxiety-di-d661ffd8150d9693Pharma Surgeen2026-06-24T00:00:00.000ZA Pragmatic SMART Study of Medication and CBT Sequencing in Pediatric Anxiety Disorders: A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/roles-and-responsibilities-of-nutrition-nurses-276776f212b8275cPharma Surgeen2026-06-24T00:00:00.000ZRoles and Responsibilities of Nutrition Nurseshttps://www.pharmaradar360.com/article/periprocedural-cooling-during-botulinum-toxin-injection-surface-temperature-effe-fd9899277cccc93dPharma Surgeen2026-06-24T00:00:00.000ZPeriprocedural Cooling During Botulinum Toxin Injection: Surface Temperature Effects and Practical Clinical Considerationshttps://www.pharmaradar360.com/article/a-conversation-with-malcolm-willett-cartoonist-who-looks-at-us-with-a-wry-smile-808ddde23a1a2047Pharma Surgeen2026-06-24T00:00:00.000ZA Conversation With ... Malcolm Willett, Cartoonist Who Looks at Us With a Wry Smilehttps://www.pharmaradar360.com/article/real-world-recurrence-free-and-distant-metastasis-free-survival-in-early-stage-m-7ea54ece45e9f036Pharma Surgeen2026-06-24T00:00:00.000ZReal-world recurrence-free and distant metastasis-free survival in early-stage melanoma: concordance with KEYNOTE-716 trial estimateshttps://www.pharmaradar360.com/article/a-multi-centre-real-world-evaluation-of-ritlecitinib-in-severe-alopecia-areata-e-7374fdb196c99c80Pharma Surgeen2026-06-24T00:00:00.000ZA Multi-Centre Real-World Evaluation of Ritlecitinib in Severe Alopecia Areata: Early Real World Experience in a British Cohorthttps://www.pharmaradar360.com/article/a-review-of-male-genital-psoriasis-cbb089bbaba85d3bPharma Surgeen2026-06-24T00:00:00.000ZA Review of Male Genital Psoriasishttps://www.pharmaradar360.com/article/a-novel-drug-screening-strategy-based-on-non-invasive-electrochemical-detection-70c5f534dbc7cb98Pharma Surgeen2026-06-24T00:00:00.000ZA novel drug screening strategy based on non-invasive electrochemical detection of multiple tumor markers secreted by patient-derived microgel organoidshttps://www.pharmaradar360.com/article/neurobiomarker-guided-neuromodulation-for-youth-with-major-depressive-episodes-a-c7b9886c42124586Pharma Surgeen2026-06-24T00:00:00.000ZNeurobiomarker-guided neuromodulation for youth with major depressive episodes: a double-blind randomized trialhttps://www.pharmaradar360.com/article/from-breadth-to-depth-in-clinical-artificial-intelligence-evaluation-3dd8d26301e31542Pharma Surgeen2026-06-24T00:00:00.000ZFrom breadth to depth in clinical artificial intelligence evaluationhttps://www.pharmaradar360.com/article/retraction-note-carbon-nano-onion-mediated-dual-targeting-of-p-selectin-and-p-gl-7c5d9f5978a9c44dPharma Surgeen2026-06-24T00:00:00.000ZRetraction Note: Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistancehttps://www.pharmaradar360.com/article/aprepitant-s-neuroprotective-effects-on-methylphenidate-induced-biochemical-mito-e3bd11b8177cb3daPharma Surgeen2026-06-24T00:00:00.000ZAprepitant’s neuroprotective effects on methylphenidate-induced biochemical/mitochondrial dysfunction, neuroinflammation, and mood-related behavior alterationshttps://www.pharmaradar360.com/article/mechanistic-insights-into-lgals3-mediated-osteoarthritis-progression-activation-a50ce0658f97c300Pharma Surgeen2026-06-24T00:00:00.000ZMechanistic Insights into LGALS3-Mediated Osteoarthritis Progression: Activation of the cGAS-STING Pathway as a Key Driver of Senescence-Related Osteoarthritishttps://www.pharmaradar360.com/article/multiparametric-characterization-of-tough-clots-following-stroke-thrombectomy-7c15a6a06bfaaeb7Pharma Surgeen2026-06-24T00:00:00.000ZMultiparametric Characterization of Tough Clots Following Stroke Thrombectomyhttps://www.pharmaradar360.com/article/protected-time-for-clinical-investigators-in-medical-oncology-the-persistent-gap-34ed88200a00aeccPharma Surgeen2026-06-24T00:00:00.000Z“Protected time” for clinical investigators in medical oncology: The persistent gap between expectation and realityhttps://www.pharmaradar360.com/article/nvidia-bets-on-agentic-ai-to-turbocharge-biotech-discovery-e1bab1612da854bfPharma Surgeen2026-06-23T23:52:28.000ZNvidia bets on agentic AI to turbocharge biotech discoveryhttps://www.pharmaradar360.com/article/lilly-astellas-circle-sangamo-assets-as-biotech-files-for-bankruptcy-83e7b78763dfa4ddPharma Surgeen2026-06-23T23:34:53.000ZLilly, Astellas circle Sangamo assets as biotech files for bankruptcyhttps://www.pharmaradar360.com/article/european-commission-approves-padcevtm-enfortumab-vedotin-in-combination-with-key-cb0f40e00c75fc97Pharma Surgeen2026-06-23T23:30:00.000ZEuropean Commission Approves PADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) as the First and Only Approved Perioperative Treatment Option for Cisplatin-Ineligible Patients with Resectable Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/china-s-biotech-boom-record-5-215-clinical-drug-trials-reported-in-2025-512cbe9901526da7Pharma Surgeen2026-06-23T23:00:06.000ZChina’s biotech boom: record 5,215 clinical drug trials reported in 2025https://www.pharmaradar360.com/article/diet-pill-death-triggers-raids-525083a8d1d6f840Pharma Surgeen2026-06-23T22:20:02.000ZDiet pill death triggers raidshttps://www.pharmaradar360.com/article/key-takeaways-leveraging-china-s-biotech-ecosystem-62b2ecb59640e3fbPharma Surgeen2026-06-23T22:01:09.000ZKey Takeaways | Leveraging China’s biotech ecosystemhttps://www.pharmaradar360.com/article/base-editing-biotech-launches-straight-onto-nasdaq-in-reverse-merger-with-boundl-5e82d191d061890ePharma Surgeen2026-06-23T21:14:34.000ZBase-editing biotech launches straight onto NASDAQ in reverse merger with Boundlesshttps://www.pharmaradar360.com/article/biotech-blues-the-not-so-hidden-costs-of-prior-art-lessons-in-pharma-and-psyched-b27b52402293421aPharma Surgeen2026-06-23T20:37:54.000ZBiotech Blues & The Not-So-Hidden Costs of Prior Art: Lessons in Pharma and Psychedelicshttps://www.pharmaradar360.com/article/biotech-etfs-gain-momentum-via-ai-drug-discovery-surging-m-a-29c0578045a88b45Pharma Surgeen2026-06-23T20:29:09.000ZBiotech ETFs Gain Momentum via AI Drug Discovery & Surging M&Ahttps://www.pharmaradar360.com/article/biotech-s-silent-resurgence-5-year-base-breakout-0a3973d729d9754cPharma Surgeen2026-06-23T20:17:00.000ZBiotech's Silent Resurgence (5-Year Base Breakout)https://www.pharmaradar360.com/article/chlorthalidone-blood-pressure-drug-recalled-nationwide-after-fda-warning-925654448d9a3225Pharma Surgeen2026-06-23T20:15:57.000ZChlorthalidone Blood Pressure Drug Recalled Nationwide After FDA Warninghttps://www.pharmaradar360.com/article/fda-pilot-targets-faster-early-stage-drug-trial-starts-pharmexec-d9707c6b7d603b7ePharma Surgeen2026-06-23T20:12:58.000ZFDA Pilot Targets Faster Early-Stage Drug Trial Starts | PharmExechttps://www.pharmaradar360.com/article/revolution-medicines-rvmd-initiates-phase-3-trial-for-pancreatic-cancer-treatmen-b4b4adf8de6f4390Pharma Surgeen2026-06-23T20:11:10.000ZRevolution Medicines (RVMD) Initiates Phase 3 Trial for Pancreatic Cancer Treatmenthttps://www.pharmaradar360.com/article/retail-investors-say-don-t-miss-this-top-biotech-stock-with-huge-upside-potentia-b1e76638783de56ePharma Surgeen2026-06-23T19:56:45.000ZRetail Investors Say Don’t Miss This Top Biotech Stock With Huge Upside Potentialhttps://www.pharmaradar360.com/article/bio-2026-nvidia-announces-the-bionemo-toolkit-for-ai-agents-648fcc1746f19184Pharma Surgeen2026-06-23T19:41:15.000ZBIO 2026: NVIDIA announces the BioNeMo toolkit for AI agentshttps://www.pharmaradar360.com/article/sen-gillibrand-raises-concerns-about-china-s-ability-to-attract-u-s-biotech-inve-a4c2670ff0be8275Pharma Surgeen2026-06-23T19:25:23.000ZSen. Gillibrand Raises Concerns About China’s Ability To Attract U.S. Biotech Investment, Partnershttps://www.pharmaradar360.com/article/exclusive-pro-life-groups-press-todd-blanche-to-settle-fda-mail-in-abortion-pill-630936c463b45f64Pharma Surgeen2026-06-23T18:53:56.000ZExclusive | Pro-life groups press Todd Blanche to settle FDA mail-in abortion pill case: ‘Unborn children are killed’https://www.pharmaradar360.com/article/haisco-licenses-two-drug-candidates-to-nuvectis-for-40m-upfront-by-investing-com-104f0663e2b14366Pharma Surgeen2026-06-23T18:41:32.000ZHaisco licenses two drug candidates to Nuvectis for $40m upfront By Investing.comhttps://www.pharmaradar360.com/article/pharmaceutical-trade-group-files-lawsuits-to-block-state-laws-on-pbms-c1d14cfac9dd77dfPharma Surgeen2026-06-23T18:38:28.000ZPharmaceutical Trade Group Files Lawsuits to Block State Laws on PBMshttps://www.pharmaradar360.com/article/discreet-biotech-osanni-bio-starts-making-noise-with-190m-series-b-for-clinical-ec5b4d05223060d7Pharma Surgeen2026-06-23T18:28:07.000ZDiscreet biotech Osanni Bio starts making noise with $190M series B for clinical pushhttps://www.pharmaradar360.com/article/serapha-bio-takes-flight-from-boundless-merger-with-230m-and-gene-editing-prospe-a7454d1e9469cc1ePharma Surgeen2026-06-23T17:55:35.000ZSerapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from Chinahttps://www.pharmaradar360.com/article/fda-changes-rare-disease-tune-again-as-it-clears-path-for-regenxbio-s-gene-thera-774399748468386ePharma Surgeen2026-06-23T17:46:37.000ZFDA changes rare disease tune again as it clears path for Regenxbio’s gene therapyhttps://www.pharmaradar360.com/article/update-lilly-astellas-circle-sangamo-assets-as-biotech-files-for-bankruptcy-8324c3daefbe6634Pharma Surgeen2026-06-23T17:35:00.000ZUPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcyhttps://www.pharmaradar360.com/article/pro-life-doctors-urge-fda-to-reinstate-abortion-pill-safeguards-ecf30141dc812a34Pharma Surgeen2026-06-23T16:50:00.000ZPro-Life Doctors Urge FDA to Reinstate Abortion Pill Safeguardshttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-verrica-stock-rating-on-trial-progress-bddc8e6cc081c74bPharma Surgeen2026-06-23T16:47:43.000ZH.C. Wainwright reiterates Verrica stock rating on trial progresshttps://www.pharmaradar360.com/article/apifix-46d2d81a536c4a0fPharma Surgeen2026-06-23T16:28:37.000ZApiFix®https://www.pharmaradar360.com/article/u-s-global-health-legislation-tracker-ec916851cb08fd5cPharma Surgeen2026-06-23T16:27:00.000ZU.S. Global Health Legislation Trackerhttps://www.pharmaradar360.com/article/certara-launches-bio-venture-catalyst-for-emerging-biotechs-to-de-risk-investmen-285e38daf51b4e87Pharma Surgeen2026-06-23T16:23:54.000ZCertara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Developmenthttps://www.pharmaradar360.com/article/sanofi-multiple-sclerosis-drug-gets-eu-approval-despite-fda-letter-sanofi-nasdaq-3e896f367a324190Pharma Surgeen2026-06-23T16:21:34.000ZSanofi Multiple Sclerosis Drug Gets EU Approval Despite FDA Letter - Sanofi (NASDAQ:SNY)https://www.pharmaradar360.com/article/integrating-endogenous-ligand-competition-into-a-mechanistic-whole-body-pbpk-mod-dc624ab93f1623c5Pharma Surgeen2026-06-23T16:01:47.000ZIntegrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodieshttps://www.pharmaradar360.com/article/urgent-public-health-messages-0fe32b0d2989273fPharma Surgeen2026-06-23T16:00:19.000ZUrgent public health messageshttps://www.pharmaradar360.com/article/personal-protective-equipment-and-heat-risk-of-heat-stress-4e57439b6595dceaPharma Surgeen2026-06-23T16:00:14.000ZPersonal protective equipment and heat: risk of heat stresshttps://www.pharmaradar360.com/article/uld-container-vs-non-uld-container-what-is-the-difference-1d6f91f02d1e259fPharma Surgeen2026-06-23T15:40:56.000ZULD Container vs.Non-ULD Container: What Is the Difference?https://www.pharmaradar360.com/article/63-runs-and-no-convergence-when-rsnlme-succeeded-where-others-couldn-t-e3c26a63c947bf74Pharma Surgeen2026-06-23T15:40:06.000Z63 Runs and No Convergence: When RsNLME Succeeded Where Others Couldn’thttps://www.pharmaradar360.com/article/cordis-project-european-african-vaccine-initiative-eavi-accelerating-preventive-450f5665b25341fdPharma Surgeen2026-06-23T15:36:12.000ZCORDIS project: EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB-SAHARAN AFRICAhttps://www.pharmaradar360.com/article/cordis-project-spatial-crosstalk-in-immuno-oncology-125d828393882e8dPharma Surgeen2026-06-23T15:33:43.000ZCORDIS project: Spatial Crosstalk in Immuno-Oncologyhttps://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-27-report-data-to-week-26-data-up-t-39d0cd44b81694a0Pharma Surgeen2026-06-23T15:32:44.000ZNational norovirus and rotavirus report, week 27 report: data to week 26 (data up to 28 June 2026)https://www.pharmaradar360.com/article/witness-carolina-s-role-in-the-revolutionary-war-950bffcb032a61c8Pharma Surgeen2026-06-23T15:31:34.000Z‘Witness’ Carolina’s role in the Revolutionary Warhttps://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-9354f373822a4db7Pharma Surgeen2026-06-23T15:30:38.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, May 2025 to May 2026https://www.pharmaradar360.com/article/ns-035-ad3fe6ba9e021a37Pharma Surgeen2026-06-23T15:30:00.000Z福山型先天性筋ジストロフィー治療剤「NS-035」希少疾病用医薬品指定のお知らせhttps://www.pharmaradar360.com/article/64eecea013c8434fPharma Surgeen2026-06-23T15:30:00.000Zボストン小児病院との共同研究契約締結のお知らせhttps://www.pharmaradar360.com/article/the-first-90-days-after-fda-clearance-greenlight-guru-4dbaf47997c9ea77Pharma Surgeen2026-06-23T15:26:40.000ZThe first 90 days after FDA clearance | Greenlight Guruhttps://www.pharmaradar360.com/article/cordis-project-next-generation-toolbox-for-greener-pharmaceuticals-design-manufa-54347cb6058aea6aPharma Surgeen2026-06-23T15:23:36.000ZCORDIS project: Next generation toolbox for greener pharmaceuticals design & manufacturing towards reduced environmental impacthttps://www.pharmaradar360.com/article/field-safety-notices-15-to-19-june-2026-0dae56725b81dbb3Pharma Surgeen2026-06-23T15:23:17.000ZField Safety Notices: 15 to 19 June 2026https://www.pharmaradar360.com/article/reforming-the-general-medical-council-legislative-framework-d5e8f0967636328aPharma Surgeen2026-06-23T15:17:27.000ZReforming the General Medical Council legislative frameworkhttps://www.pharmaradar360.com/article/the-tea-in-your-kombucha-changes-more-than-just-the-taste-922ed75d23508a0bPharma Surgeen2026-06-23T15:06:00.000ZThe tea in your kombucha changes more than just the tastehttps://www.pharmaradar360.com/article/la-unlp-realizara-una-jornada-de-asesoramiento-previsional-0d92d5ca55059efaPharma Surgeen2026-06-23T15:05:43.000ZLa UNLP realizará una jornada de asesoramiento previsionalhttps://www.pharmaradar360.com/article/nueva-entrega-de-computadoras-a-estudiantes-de-la-unlp-f5fac08c2fd2a85dPharma Surgeen2026-06-23T15:05:06.000ZNueva entrega de computadoras a estudiantes de la UNLPhttps://www.pharmaradar360.com/article/fda-clears-investigational-new-drug-application-for-remyelinating-agent-ptd802-i-fe8f227bc03ebcc2Pharma Surgeen2026-06-23T15:00:36.000ZFDA Clears Investigational New Drug Application for Remyelinating Agent PTD802 in Multiple Sclerosishttps://www.pharmaradar360.com/article/huella-hidrica-c1ca10512b51cc09Pharma Surgeen2026-06-23T14:59:24.000ZHuella hídricahttps://www.pharmaradar360.com/article/palabras-del-presidente-fernando-tauber-en-el-inicio-de-su-gestion-2026-2030-9a9dbd51e9b55d1dPharma Surgeen2026-06-23T14:57:40.000ZPalabras del Presidente Fernando Tauber en el inicio de su gestión 2026-2030https://www.pharmaradar360.com/article/pittsburgh-business-leader-to-head-2026-heart-walk-and-citywide-push-for-cpr-rea-916f5884ac4bd6a2Pharma Surgeen2026-06-23T14:57:00.000ZPittsburgh business leader to head 2026 Heart Walk and citywide push for CPR readinesshttps://www.pharmaradar360.com/article/jornada-de-buen-trato-hacia-las-personas-mayores-db8a1513d3e95feaPharma Surgeen2026-06-23T14:55:25.000ZJornada de buen trato hacia las personas mayoreshttps://www.pharmaradar360.com/article/pfizer-lung-cancer-drug-misses-key-survival-goal-in-phase-3-trial-8b3d1bf2adcc60eaPharma Surgeen2026-06-23T14:39:57.000ZPfizer lung cancer drug misses key survival goal in Phase 3 trialhttps://www.pharmaradar360.com/article/adult-social-care-data-collection-september-2025-notice-9f4a973804b186c3Pharma Surgeen2026-06-23T14:39:42.000ZAdult social care data collection: September 2025 noticehttps://www.pharmaradar360.com/article/pfizer-lung-cancer-drug-sigvotatug-vedotin-fails-phase-3-trial-887a8d9f613040c8Pharma Surgeen2026-06-23T14:39:12.000ZPfizer lung cancer drug sigvotatug vedotin fails phase 3 trialhttps://www.pharmaradar360.com/article/cpa-da-ufrj-define-coordenacao-e-planeja-proximos-passos-da-avaliacao-institucio-8f80df7fa0acbbefPharma Surgeen2026-06-23T14:35:00.000ZCPA da UFRJ define coordenação e planeja próximos passos da avaliação institucionalhttps://www.pharmaradar360.com/article/scientists-finally-solved-how-h5n1-bird-flu-hid-in-dairy-cows-0bc6afc35a6a5a50Pharma Surgeen2026-06-23T14:31:51.000ZScientists finally solved how H5N1 bird flu hid in dairy cowshttps://www.pharmaradar360.com/article/performance-of-the-techcyte-ai-based-image-analysis-system-for-coproparasitologi-f52fee6ab651e077Pharma Surgeen2026-06-23T14:23:29.000ZPerformance of the Techcyte AI-based image analysis system for coproparasitological diagnosis in clinical stool specimens: a retrospective evaluation studyhttps://www.pharmaradar360.com/article/the-fortin-family-foundation-makes-extraordinary-5-million-gift-to-the-campaign-ca842f128560900bPharma Surgeen2026-06-23T14:23:07.000ZThe Fortin Family Foundation Makes Extraordinary $5 Million Gift to the Campaign for St. Vincent Regional Hospitalhttps://www.pharmaradar360.com/article/medicines-eligible-for-northern-ireland-mhra-authorised-route-ea4846a98bf6c2a7Pharma Surgeen2026-06-23T14:17:25.000ZMedicines eligible for Northern Ireland MHRA Authorised Routehttps://www.pharmaradar360.com/article/merck-kgaa-pledges-50m-to-new-biotech-with-eye-to-acquisition-0c97d126c0f31953Pharma Surgeen2026-06-23T14:16:26.000ZMerck KGaA pledges $50M to new biotech with eye to acquisitionhttps://www.pharmaradar360.com/article/las-invasiones-inglesas-y-el-nacimiento-de-una-identidad-nacional-5ff061e1aeaee733Pharma Surgeen2026-06-23T14:08:13.000ZLas Invasiones Inglesas y el nacimiento de una identidad nacionalhttps://www.pharmaradar360.com/article/pfizer-pfe-lung-cancer-drug-misses-survival-goal-in-phase-3-trial-0c7871d67c93cf30Pharma Surgeen2026-06-23T14:06:26.000ZPfizer (PFE) Lung Cancer Drug Misses Survival Goal In Phase 3 Trialhttps://www.pharmaradar360.com/article/ananda-pharma-confirms-safety-of-cbd-drug-as-clinical-pain-trials-approach-c665f71802097e49Pharma Surgeen2026-06-23T14:05:57.000ZAnanda Pharma Confirms Safety of CBD Drug, as Clinical Pain Trials Approachhttps://www.pharmaradar360.com/article/homenaje-a-la-bandera-en-los-jardines-del-rectorado-df0d43f386ffd1cbPharma Surgeen2026-06-23T13:59:59.000ZHomenaje a la Bandera en los jardines del Rectoradohttps://www.pharmaradar360.com/article/application-of-io-simulator-in-immuno-oncology-combination-therapy-a-small-cell-3d00c4089200d552Pharma Surgeen2026-06-23T13:58:37.000ZApplication of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Studyhttps://www.pharmaradar360.com/article/breve-elogio-sobre-la-libertad-academica-b735fca67b2a4d6cPharma Surgeen2026-06-23T13:57:55.000ZBreve elogio sobre la libertad académicahttps://www.pharmaradar360.com/article/the-medical-frailty-exemption-from-medicaid-work-requirements-key-takeaways-from-60411ed4c27b4044Pharma Surgeen2026-06-23T13:55:48.000ZThe Medical Frailty Exemption from Medicaid Work Requirements: Key Takeaways from the CMS Interim Final Rulehttps://www.pharmaradar360.com/article/fourteen-oxford-academics-awarded-major-european-research-council-advanced-grant-6f61084b1c8139d5Pharma Surgeen2026-06-23T13:53:43.000ZFourteen Oxford academics awarded major European Research Council Advanced Grantshttps://www.pharmaradar360.com/article/strategic-health-purchasing-as-an-enabler-of-health-systems-resilience-in-fragil-87d57da5ee7b76eePharma Surgeen2026-06-23T13:47:24.000ZStrategic Health Purchasing as an Enabler of Health Systems Resilience in Fragile States: Evidence from South Sudanhttps://www.pharmaradar360.com/article/fortitude-and-heartsciences-nasdaq-hscs-announce-business-combination-aiming-to-3980f5efadd81bc3Pharma Surgeen2026-06-23T13:44:56.000ZFortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Marketshttps://www.pharmaradar360.com/article/mas-sustentable-la-unlp-redujo-un-12-su-huella-de-carbono-dc3615e7287227ecPharma Surgeen2026-06-23T13:44:30.000ZMás sustentable: la UNLP redujo un 12% su huella de carbonohttps://www.pharmaradar360.com/article/la-unlp-reunio-a-mas-de-40-equipos-editoriales-en-el-encuentro-de-revistas-cient-ac9de3f9fd2728c9Pharma Surgeen2026-06-23T13:43:52.000ZLa UNLP reunió a más de 40 equipos editoriales en el Encuentro de Revistas Científicashttps://www.pharmaradar360.com/article/jornada-por-el-dia-mundial-del-ambiente-accion-por-el-clima-del-saber-al-hacer-37181135bcdc5ec7Pharma Surgeen2026-06-23T13:43:10.000ZJornada por el día mundial del ambiente: acción por el clima, del saber al hacerhttps://www.pharmaradar360.com/article/la-unlp-realizo-una-nueva-colecta-de-sangre-y-jornada-integral-de-salud-fe045f3184c5898bPharma Surgeen2026-06-23T13:42:30.000ZLa UNLP realizó una nueva colecta de sangre y jornada integral de saludhttps://www.pharmaradar360.com/article/agenda-conjunta-con-la-union-de-parlamentarios-sudamericanos-764a255dfc8902b0Pharma Surgeen2026-06-23T13:38:16.000ZAgenda conjunta con la Unión de Parlamentarios Sudamericanoshttps://www.pharmaradar360.com/article/tauber-recorrio-las-obras-del-edificio-anexo-de-derecho-80e838733cabaa73Pharma Surgeen2026-06-23T13:36:36.000ZTauber recorrió las obras del edificio Anexo de Derechohttps://www.pharmaradar360.com/article/jornada-por-una-universidad-libre-de-humo-y-nicotina-5e6696bbbe94980fPharma Surgeen2026-06-23T13:34:02.000ZJornada por una Universidad libre de humo y nicotinahttps://www.pharmaradar360.com/article/la-unlp-y-china-afianzan-lazos-de-cooperacion-con-la-inauguracion-de-un-nuevo-ce-b656851b1493f8dcPharma Surgeen2026-06-23T13:33:25.000ZLa UNLP y China afianzan lazos de cooperación con la inauguración de un nuevo centro culturalhttps://www.pharmaradar360.com/article/measuring-the-pull-side-innovation-burden-for-pharmaceutical-drugs-by-oecd-count-99381439bf77007cPharma Surgeen2026-06-23T13:33:25.000ZMeasuring the Pull-Side Innovation Burden for Pharmaceutical Drugs by OECD Countryhttps://www.pharmaradar360.com/article/revolution-medicines-begins-phase-3-trial-for-pancreatic-cancer-15d1ae6150e07ef5Pharma Surgeen2026-06-23T13:31:31.000ZRevolution Medicines begins phase 3 trial for pancreatic cancerhttps://www.pharmaradar360.com/article/galectin-reaches-fda-agreement-on-phase-3-trial-for-belapectin-9afd3d197807afddPharma Surgeen2026-06-23T13:25:45.000ZGalectin reaches FDA agreement on Phase 3 trial for belapectinhttps://www.pharmaradar360.com/article/revolutionary-copd-injection-given-to-patients-for-first-time-261b7d9eb2567bdfPharma Surgeen2026-06-23T13:24:12.000ZRevolutionary COPD injection given to patients for first timehttps://www.pharmaradar360.com/article/what-makes-mri-the-perfect-fit-for-interventional-workflows-these-pioneers-expla-c83c049dc6a0954bPharma Surgeen2026-06-23T13:17:45.000ZWhat Makes MRI the Perfect Fit for Interventional Workflows? These Pioneers Explain.https://www.pharmaradar360.com/article/de-risk-adenoviral-vector-development-with-an-adaptive-platform-73e51507005b33eePharma Surgeen2026-06-23T13:10:00.000ZDe-Risk Adenoviral Vector Development with an Adaptive Platformhttps://www.pharmaradar360.com/article/sk-pharmteco-announces-skyvectm-a-unified-high-yield-viral-vector-platform-desig-fe7647be36171d83Pharma Surgeen2026-06-23T13:05:00.000ZSK pharmteco Announces SKyvec™, A Unified, High-Yield Viral Vector Platform Designed to Accelerate Gene Therapy Development from Batch to Bedsidehttps://www.pharmaradar360.com/article/mechanistic-modelling-of-crs-in-t-cell-engagers-an-application-for-blinatumomab-310fc062f187c580Pharma Surgeen2026-06-23T12:59:15.000ZMechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomabhttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-29776fbc92997ea0Pharma Surgeen2026-06-23T12:59:11.000ZTracking Implementation of the 2025 Reconciliation Law Medicaid Work Requirements: Related Resourceshttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-da141fb5d19965f4Pharma Surgeen2026-06-23T12:59:06.000ZTracking Implementation of the 2025 Reconciliation Law Medicaid Work Requirements: 1115-waivershttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-38463bac8179533dPharma Surgeen2026-06-23T12:59:01.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirements Implementation Questionshttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-6639d664866d5eddPharma Surgeen2026-06-23T12:58:56.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirementshttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-f066079fc0240f7ePharma Surgeen2026-06-23T12:58:10.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirements Data and Policieshttps://www.pharmaradar360.com/article/easygrid-towards-better-automation-in-cryo-electron-microscopy-3e5dc74d617e422dPharma Surgeen2026-06-23T12:39:38.000ZEasyGrid: towards better automation in cryo-electron microscopyhttps://www.pharmaradar360.com/article/fda-approval-of-semaglutide-for-weight-loss-spurs-surge-in-u-s-poison-control-ca-a6dd53fcdcfdf13aPharma Surgeen2026-06-23T12:34:30.000ZFDA Approval of Semaglutide for Weight Loss Spurs Surge in U.S. Poison Control Calls, UT San Antonio Study Findshttps://www.pharmaradar360.com/article/pfizer-delivers-disappointing-late-stage-lung-cancer-data-for-adc-from-43b-seage-5d299ffc93c517a3Pharma Surgeen2026-06-23T12:31:14.000ZPfizer delivers ‘disappointing’ late-stage lung cancer data for ADC from $43B Seagen buyhttps://www.pharmaradar360.com/article/medication-abortion-decisions-from-federal-courts-the-fda-or-trump-s-department-d38d4aa748308a24Pharma Surgeen2026-06-23T12:29:44.000ZMedication abortion: Decisions from federal courts, the FDA or Trump’s Department of Justice could try to end access via telehealthhttps://www.pharmaradar360.com/article/basic-science-research-retreat-aims-at-collaboration-2be2816482c0c999Pharma Surgeen2026-06-23T12:19:57.000ZBasic science research retreat aims at collaborationhttps://www.pharmaradar360.com/article/dr-erickson-to-take-new-continuing-education-role-f8e68238ad39ff4dPharma Surgeen2026-06-23T12:18:56.000ZDr. Erickson to take new continuing education rolehttps://www.pharmaradar360.com/article/regan-taylor-md-named-director-of-phase-2-7fa1c7f864285b93Pharma Surgeen2026-06-23T12:17:40.000ZRegan Taylor, MD, named director of Phase 2https://www.pharmaradar360.com/article/medical-research-highlights-june-2026-ee724de04515f5f0Pharma Surgeen2026-06-23T12:15:30.000ZMedical research highlights, June 2026https://www.pharmaradar360.com/article/mello-finishes-term-as-aamc-steering-committee-chair-7c68909bd57d0202Pharma Surgeen2026-06-23T12:14:05.000ZMello finishes term as AAMC steering committee chairhttps://www.pharmaradar360.com/article/galectin-therapeutics-reaches-fda-agreement-on-phase-3-endpoint-and-regulatory-p-0333432677d55bd8Pharma Surgeen2026-06-23T12:13:00.000ZGalectin Therapeutics Reaches FDA Agreement on Phase 3 Endpoint and Regulatory Path for Belapectin Full Approvalhttps://www.pharmaradar360.com/article/retirement-reception-july-28-for-shantaram-joshi-phd-a85f739d9b73b238Pharma Surgeen2026-06-23T12:12:52.000ZRetirement reception July 28 for Shantaram Joshi, PhDhttps://www.pharmaradar360.com/article/allergy-and-immunology-fellowship-program-nets-acaai-grant-6806eeffbaea87cePharma Surgeen2026-06-23T12:11:33.000ZAllergy and immunology fellowship program nets ACAAI granthttps://www.pharmaradar360.com/article/dean-s-message-applause-thanks-and-holiday-best-wishes-2e9f1f6db09b3a0ePharma Surgeen2026-06-23T12:10:27.000ZDean’s message: Applause, thanks and holiday best wisheshttps://www.pharmaradar360.com/article/new-brain-study-reveals-speech-learning-works-differently-than-we-thought-3b2266764e9f6a6dPharma Surgeen2026-06-23T12:06:13.000ZNew brain study reveals speech learning works differently than we thoughthttps://www.pharmaradar360.com/article/rector-and-dean-of-unsw-canberra-visits-kyoto-university-c3aa348e327826aePharma Surgeen2026-06-23T12:00:00.000ZRector and Dean of UNSW Canberra visits Kyoto Universityhttps://www.pharmaradar360.com/article/optima-xr240amx-x-ray-system-0f96260a3403cd89Pharma Surgeen2026-06-23T12:00:00.000ZOptima XR240amx X-Ray Systemhttps://www.pharmaradar360.com/article/hoffmann-ii-carbon-connecting-rod-f7e8d926ffd8e318Pharma Surgeen2026-06-23T12:00:00.000ZHoffmann® II Carbon Connecting Rodhttps://www.pharmaradar360.com/article/a-t-s-4000-ts-tourniquet-systems-single-and-dual-hose-with-cpc-connectors-bd9e9ccfa5511039Pharma Surgeen2026-06-23T12:00:00.000ZA.T.S® 4000 TS Tourniquet Systems Single and Dual Hose with CPC Connectorshttps://www.pharmaradar360.com/article/revolution-medicines-opens-phase-3-pancreatic-cancer-trial-with-zoldonrasib-30044403872243fePharma Surgeen2026-06-23T12:00:00.000ZRevolution Medicines opens Phase 3 pancreatic cancer trial with zoldonrasibhttps://www.pharmaradar360.com/article/revolution-medicines-begins-treating-patients-in-rasolute-305-a-phase-3-clinical-9b77e9f06d129789Pharma Surgeen2026-06-23T12:00:00.000ZRevolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancerhttps://www.pharmaradar360.com/article/allergan-aesthetics-receives-approval-for-boey-trenibotulinumtoxine-in-canada-th-f5cf71c0df5d0e56Pharma Surgeen2026-06-23T12:00:00.000ZAllergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patientshttps://www.pharmaradar360.com/article/withdrawn-cancer-accelerated-approvals-9d91fd407d4e65c0Pharma Surgeen2026-06-23T11:52:49.000ZWithdrawn | Cancer Accelerated Approvalshttps://www.pharmaradar360.com/article/university-athletes-set-to-shine-at-glasgow-2026-b4d60e6289c20addPharma Surgeen2026-06-23T11:44:12.000ZUniversity athletes set to shine at Glasgow 2026https://www.pharmaradar360.com/article/volantetm-steerable-guiding-sheath-now-available-in-us-f121ffe7b3f918a3Pharma Surgeen2026-06-23T11:43:23.000ZVolante™ Steerable Guiding Sheath now available in UShttps://www.pharmaradar360.com/article/high-quality-workshop-on-global-health-economics-in-low-and-middle-income-countr-4d4f46a0ffea2cb7Pharma Surgeen2026-06-23T11:40:00.000ZHigh quality workshop on Global Health Economics in low- and middle-income countrieshttps://www.pharmaradar360.com/article/antidepressant-recall-expands-across-the-u-s-289d3e5b3a83d4f6Pharma Surgeen2026-06-23T11:36:46.000ZAntidepressant Recall Expands Across the U.S.https://www.pharmaradar360.com/article/rethinking-alzheimer-s-clinical-trials-to-include-atypical-forms-of-the-disease-a766d0ec456d1a33Pharma Surgeen2026-06-23T11:32:00.000ZRethinking Alzheimer’s clinical trials to include atypical forms of the diseasehttps://www.pharmaradar360.com/article/one-of-the-world-s-most-popular-weedkillers-may-be-fueling-deadly-superbugs-ae82ebc3cb1f9dbePharma Surgeen2026-06-23T11:31:51.000ZOne of the world’s most popular weedkillers may be fueling deadly superbugshttps://www.pharmaradar360.com/article/pfizer-s-first-new-adc-from-seagen-acquisition-fails-phase-3-nsclc-trial-54eb83b166e1d4a7Pharma Surgeen2026-06-23T11:15:24.000ZPfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trialhttps://www.pharmaradar360.com/article/glp-1s-took-drug-compounding-to-a-new-level-empower-pharmacy-cashed-in-0c36dbe368f9daa8Pharma Surgeen2026-06-23T11:05:44.000ZGLP-1s took drug compounding to a new level. Empower Pharmacy cashed in.https://www.pharmaradar360.com/article/dating-fraudsters-gain-your-trust-first-then-your-money-1170b95d099e622dPharma Surgeen2026-06-23T11:05:36.000ZDating fraudsters gain your trust first, then your moneyhttps://www.pharmaradar360.com/article/nuvectis-nasdaq-nvct-inks-haisco-deal-for-nxp100-and-braf-drug-nxp200-7021503a6d0df88fPharma Surgeen2026-06-23T11:00:41.000ZNuvectis (NASDAQ: NVCT) inks Haisco deal for NXP100 and BRAF drug NXP200https://www.pharmaradar360.com/article/uncommon-cancers-common-goals-overcoming-the-challenges-of-rare-cancer-research-34d442ed19f1eff1Pharma Surgeen2026-06-23T11:00:00.000ZUncommon Cancers, Common Goals: Overcoming the Challenges of Rare Cancer Researchhttps://www.pharmaradar360.com/article/tech-executive-named-chair-of-the-2026-long-island-heart-walk-e623497f6ffe4837Pharma Surgeen2026-06-23T11:00:00.000ZTech executive named chair of the 2026 Long Island Heart Walkhttps://www.pharmaradar360.com/article/cordis-project-training-europe-s-future-leaders-in-ai-driven-neuro-oncology-diag-414290311a05d2a1Pharma Surgeen2026-06-23T10:58:13.000ZCORDIS project: Training Europe’s Future Leaders in AI-driven Neuro-Oncology Diagnostics and Discoveryhttps://www.pharmaradar360.com/article/cordis-project-first-in-class-selective-nurr1-rxr-modulators-with-a-unique-bioph-c42fbe6bdc7ba325Pharma Surgeen2026-06-23T10:58:10.000ZCORDIS project: First-in-Class Selective Nurr1:RXRα Modulators with a Unique Biophysical Mechanism driving multi-pathway Disease Modification in Parkinson’s Disease.https://www.pharmaradar360.com/article/cordis-project-the-first-multimodal-genai-platform-delivering-precision-breast-c-f9e5b3938e351a91Pharma Surgeen2026-06-23T10:58:03.000ZCORDIS project: The First Multimodal GenAI Platform Delivering Precision Breast Cancer Diagnosishttps://www.pharmaradar360.com/article/cordis-project-mapping-antigenic-niches-of-tumor-infiltrating-b-cells-in-triple-739aa1e554eef5b1Pharma Surgeen2026-06-23T10:58:02.000ZCORDIS project: Mapping antigenic niches of tumor-infiltrating B cells in triple-negative breast cancerhttps://www.pharmaradar360.com/article/how-ai-1-billion-and-a-transparent-fish-could-transform-neuroscience-ec0955807d747b86Pharma Surgeen2026-06-23T10:50:00.000ZHow AI, $1 billion, and a transparent fish could transform neurosciencehttps://www.pharmaradar360.com/article/bd-awarded-vizient-innovative-technology-contract-for-centrovena-onetm-insertion-dd54fa3453f44ac3Pharma Surgeen2026-06-23T10:50:00.000ZBD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion Systemhttps://www.pharmaradar360.com/article/two-erc-advanced-grants-awarded-to-researchers-at-the-university-of-freiburg-89b4206511fa6bf6Pharma Surgeen2026-06-23T10:49:36.000ZTwo ERC Advanced Grants awarded to researchers at the University of Freiburghttps://www.pharmaradar360.com/article/decision-marketing-authorisations-granted-in-2026-e53c9537c2a4e38cPharma Surgeen2026-06-23T10:42:49.000ZDecision: Marketing authorisations Granted in 2026https://www.pharmaradar360.com/article/decision-parallel-import-licences-granted-in-2026-416d964690a20061Pharma Surgeen2026-06-23T10:42:34.000ZDecision: Parallel import licences granted in 2026https://www.pharmaradar360.com/article/living-medicine-and-ai-designed-proteins-to-fight-lung-cancer-from-within-ed0942e26fe3e653Pharma Surgeen2026-06-23T10:35:27.000Z‘Living medicine’ and AI-designed proteins to fight lung cancer from withinhttps://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-2f4bce1535a99302Pharma Surgeen2026-06-23T10:15:23.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/polio-global-eradication-nac-and-environmental-surveillance-28a88d7a1d6b4d94Pharma Surgeen2026-06-23T10:11:44.000ZPolio: global eradication, NAC and environmental surveillancehttps://www.pharmaradar360.com/article/vaccines-europe-welcomes-new-leadership-team-42a041a278f5318ePharma Surgeen2026-06-23T10:01:05.000ZVaccines Europe Welcomes New Leadership Teamhttps://www.pharmaradar360.com/article/12-50-cbe6322095440881Pharma Surgeen2026-06-23T09:44:33.000Zฉลองครบรอบ 12 ปี อมรินทร์ทีวี และ 50 ปี อมรินทร์กรุ๊ป จัดตั้ง “กองทุนสื่อสานธรรม”https://www.pharmaradar360.com/article/atom-therapeutics-announces-first-patient-dosed-in-china-phase-3-clinical-trial-b6fb782995ac07d8Pharma Surgeen2026-06-23T09:30:00.000ZAtom Therapeutics Announces First Patient Dosed in China Phase 3 Clinical Trial of Lingdolinurad (ABP-671) for Chronic Gouthttps://www.pharmaradar360.com/article/how-lung-cancer-screening-can-save-lives-public-facing-videos-from-the-solace-pr-966ed60ce51d1430Pharma Surgeen2026-06-23T09:24:00.000ZHow Lung Cancer Screening Can Save Lives – Public-facing videos from the SOLACE Projecthttps://www.pharmaradar360.com/article/006a9c520a03653ePharma Surgeen2026-06-23T09:21:19.000Zデュルバルマブ適正使用のお願い_胃癌（アストラゼネカ株式会社）https://www.pharmaradar360.com/article/pleopharma-begins-phase-3-trial-for-cannabis-withdrawal-drug-96dd3173d6fc9740Pharma Surgeen2026-06-23T09:17:34.000ZPleoPharma Begins Phase 3 Trial for Cannabis Withdrawal Drughttps://www.pharmaradar360.com/article/is-ai-still-biased-7f532f5da849c563Pharma Surgeen2026-06-23T09:00:00.000ZIs AI (Still) Biased?https://www.pharmaradar360.com/article/abbvie-announces-european-commission-approval-of-maviret-glecaprevir-pibrentasvi-9c09ce9af9a04998Pharma Surgeen2026-06-23T09:00:00.000ZAbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infectionhttps://www.pharmaradar360.com/article/erc-advanced-grants-for-researchers-at-universitat-heidelberg-93328ec77e85e454Pharma Surgeen2026-06-23T08:59:34.000ZERC Advanced Grants for Researchers at Universität Heidelberghttps://www.pharmaradar360.com/article/strengthening-partnerships-with-patient-organizations-insights-and-opportunities-58b9a712155c34c5Pharma Surgeen2026-06-23T08:46:09.000ZStrengthening partnerships with patient organizations: insights and opportunities for progresshttps://www.pharmaradar360.com/article/rgx-121-regenxbio-bla-fda-3d6726130409a77dPharma Surgeen2026-06-23T08:45:00.000ZRGX-121：REGENXBIO社が迅速承認に向けた生物製剤承認申請（BLA）再提出についてFDAと合意https://www.pharmaradar360.com/article/22-juin-journee-nationale-de-reflexion-sur-le-don-d-organes-et-la-greffe-8e314a6584ff96e3Pharma Surgeen2026-06-23T08:44:57.000Z22 juin : journée nationale de réflexion sur le don d'organes et la greffehttps://www.pharmaradar360.com/article/dr-wouter-vaes-chief-science-officer-at-peregrion-b5d9355e183a4052Pharma Surgeen2026-06-23T08:10:57.000ZDr. Wouter Vaes - Chief Science Officer at Peregrionhttps://www.pharmaradar360.com/article/arvostettu-eu-n-miljoonarahoitus-viidelle-helsingin-yliopiston-tutkijalle-6ad47b842bb112f9Pharma Surgeen2026-06-23T08:05:14.000ZArvostettu EU:n miljoonarahoitus viidelle Helsingin yliopiston tutkijallehttps://www.pharmaradar360.com/article/ukri-launches-two-ai-research-labs-to-stay-ahead-in-global-race-3cee792585299a4bPharma Surgeen2026-06-23T08:00:34.000ZUKRI launches two AI research labs to stay ahead in global racehttps://www.pharmaradar360.com/article/fama-jallow-reaching-beyond-the-stars-to-reimagine-solutions-for-africa-8e005a58f2122bb1Pharma Surgeen2026-06-23T07:36:29.000ZFama Jallow: Reaching beyond the stars to reimagine solutions for Africahttps://www.pharmaradar360.com/article/amid-a-series-of-drug-supply-shortages-and-out-of-stock-problems-boryeong-is-tak-7763e346a45e8596Pharma Surgeen2026-06-23T07:27:01.000ZAmid a series of drug supply shortages and out-of-stock problems, Boryeong is taking the lead in sta..https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-februar-3b2232fe8c91f5e1Pharma Surgeen2026-06-23T07:26:06.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in England: February 2026https://www.pharmaradar360.com/article/die-tagesklinik-am-nct-heidelberg-wie-onkologische-pflege-ambulant-funktioniert-0a1f336559322860Pharma Surgeen2026-06-23T07:13:17.000ZDie Tagesklinik am NCT Heidelberg – Wie onkologische Pflege ambulant funktionierthttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-may-e370cce99107b990Pharma Surgeen2026-06-23T07:03:34.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in England: May 2026https://www.pharmaradar360.com/article/a-message-from-leadership-on-joint-accreditation-d61d71311e703424Pharma Surgeen2026-06-23T07:02:00.000ZA message from leadership on joint accreditationhttps://www.pharmaradar360.com/article/diagnosing-a-passion-unmc-s-high-school-alliance-00040c8d71868162Pharma Surgeen2026-06-23T07:00:00.000ZDiagnosing a passion: UNMC’s High School Alliancehttps://www.pharmaradar360.com/article/abbvie-announces-european-commission-approval-of-skyrizi-risankizumab-for-the-tr-05301d26b8674ac8Pharma Surgeen2026-06-23T07:00:00.000ZAbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasishttps://www.pharmaradar360.com/article/atsena-s-atsn-201-gene-therapy-enrolls-rapidly-in-phase-3-trial-for-x-linked-ret-59d0ccf47dc3d70dPharma Surgeen2026-06-23T06:59:04.000ZAtsena’s ATSN-201 Gene Therapy Enrolls Rapidly in Phase 3 Trial for X-Linked Retinoschisishttps://www.pharmaradar360.com/article/leci-research-seminar-on-may-8th-on-educational-interventions-two-case-examples-576667014608842cPharma Surgeen2026-06-23T06:41:55.000ZLECI Research Seminar on May 8th: On educational interventions: two case examples and discussionhttps://www.pharmaradar360.com/article/why-building-long-term-value-and-making-clinical-progress-are-inextricable-be8f9fe3b24c9196Pharma Surgeen2026-06-23T06:22:21.000ZWhy Building Long-Term Value And Making Clinical Progress Are Inextricablehttps://www.pharmaradar360.com/article/flinders-business-school-launches-australia-s-first-mba-specialising-in-ai-strat-df4cfab52f936bf5Pharma Surgeen2026-06-23T06:21:25.000ZFlinders Business School launches Australia’s first MBA specialising in AI strategy and leadershiphttps://www.pharmaradar360.com/article/aimd-active-implants-scs-infinion-cx-lead-infinion-cx-c2ab1440d9c353ddPharma Surgeen2026-06-23T06:20:01.000ZΑνάκληση των αχρησιμοποίητων παρτίδων του παρακάτω πίνακα του Ιατροτεχνολογικού προϊόντος κατηγορίας AIMD Active implants, SCS Infinion CX Lead (Κιτ απαγωγής Infinion CX)https://www.pharmaradar360.com/article/result-of-agm-14618f644432fb55Pharma Surgeen2026-06-23T06:07:07.000ZResult of AGMhttps://www.pharmaradar360.com/article/five-fully-funded-fellowships-in-health-and-sustainability-open-for-applications-f153e7004d5fff1cPharma Surgeen2026-06-23T05:54:42.000ZFive fully-funded fellowships in Health and Sustainability open for applicationshttps://www.pharmaradar360.com/article/health-brief-fda-signals-reset-in-drug-reviews-03da7d5f869b1c43Pharma Surgeen2026-06-23T05:50:55.000ZHealth Brief: FDA signals reset in drug reviewshttps://www.pharmaradar360.com/article/minnesota-sugar-beet-growers-brace-for-the-possible-return-of-a-devastating-dise-7d23d1de8f7da252Pharma Surgeen2026-06-23T04:27:11.000ZMinnesota sugar beet growers brace for the possible return of a devastating diseasehttps://www.pharmaradar360.com/article/positive-psychology-aids-children-s-mental-health-92929e4d71f9770fPharma Surgeen2026-06-23T04:26:37.000ZPositive psychology aids children’s mental healthhttps://www.pharmaradar360.com/article/study-twin-cities-still-attractive-to-big-business-and-career-employees-but-conc-a95551a2031c4c1fPharma Surgeen2026-06-23T04:25:31.000ZStudy: Twin Cities still attractive to big business and career employees, but concerns emerginghttps://www.pharmaradar360.com/article/evonik-sells-hanau-pharmaceutical-ingredients-production-assets-to-prochem-6209a971c5dc25cbPharma Surgeen2026-06-23T03:12:22.000ZEvonik Sells Hanau Pharmaceutical Ingredients Production Assets To ProChemhttps://www.pharmaradar360.com/article/this-emerging-treatment-is-helping-people-avoid-knee-replacement-surgery-fcb47177d0ba499fPharma Surgeen2026-06-23T03:04:58.000ZThis emerging treatment is helping people avoid knee replacement surgeryhttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-vabysmo-partial-change-approval-43fcf402c3af1283Pharma Surgeen2026-06-23T03:00:00.000Z[SHINSA]English Translation of Review Report: Vabysmo (Partial Change Approval)https://www.pharmaradar360.com/article/small-sleep-sacks-big-compliance-lessons-what-fda-s-happiest-baby-warning-letter-f58146f67dfb2307Pharma Surgeen2026-06-23T02:45:39.000ZSmall Sleep Sacks, Big Compliance Lessons: What FDA’s Happiest Baby Warning Letter Means for Device Manufacturershttps://www.pharmaradar360.com/article/ah-008-achieves-dual-regulatory-milestones-with-u-s-fda-ind-clearance-and-taiwan-ec31dd9086e31acaPharma Surgeen2026-06-23T02:43:08.000ZAH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designationhttps://www.pharmaradar360.com/article/sls-stock-hits-over-3-year-high-as-aml-drug-trial-nears-final-readout-wall-stree-d690b1c596b74875Pharma Surgeen2026-06-23T02:20:53.000ZSLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upsidehttps://www.pharmaradar360.com/article/biotech-chief-says-industry-in-better-place-after-fda-changes-bea29e624d847877Pharma Surgeen2026-06-23T02:14:00.000ZBiotech Chief Says Industry in ‘Better Place’ After FDA Changeshttps://www.pharmaradar360.com/article/how-personal-experience-impacts-medicines-decisions-03bb66f6e7fc85f2Pharma Surgeen2026-06-23T02:00:00.000ZHow personal experience impacts medicines decisionshttps://www.pharmaradar360.com/article/funding-strengthens-rural-emergency-response-3316a90e6295a886Pharma Surgeen2026-06-23T02:00:00.000ZFunding strengthens rural emergency responsehttps://www.pharmaradar360.com/article/ensuring-continued-access-to-medicines-and-medical-devices-for-new-zealanders-18f98061a45ba9afPharma Surgeen2026-06-23T02:00:00.000ZEnsuring continued access to medicines and medical devices for New Zealandershttps://www.pharmaradar360.com/article/scientists-say-most-people-need-more-protein-than-current-guidelines-suggest-6fbae02bb7c94c87Pharma Surgeen2026-06-23T01:44:42.000ZScientists say most people need more protein than current guidelines suggesthttps://www.pharmaradar360.com/article/innovent-pfizer-deal-makes-joint-development-commercialization-pillar-in-biotech-ddb634b0622e63edPharma Surgeen2026-06-23T01:22:00.000ZInnovent-Pfizer deal makes joint development, commercialization pillar in biotech global pushhttps://www.pharmaradar360.com/article/why-this-mid-cap-biotech-could-be-the-dark-horse-threat-to-eli-lilly-and-novo-no-66bc714f3c69417cPharma Surgeen2026-06-23T01:11:55.000ZWhy This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordiskhttps://www.pharmaradar360.com/article/us-fda-declines-to-approve-achieve-life-sciences-smoking-cessation-drug-7910478bbbe4f8e2Pharma Surgeen2026-06-23T01:05:02.000ZUS FDA declines to approve Achieve Life Sciences' smoking-cessation drug